Clene Earnings Call Transcripts
Fiscal Year 2026
-
The company presented compelling clinical data for CNM-Au8 in ALS, showing significant biomarker and survival benefits, and is preparing for a key FDA meeting by end of Q1. NDA filing is targeted for Q2, with commercialization possible in early 2027, supported by recent financing.
-
A pivotal FDA meeting this quarter will review biomarker and survival data supporting accelerated approval for an ALS therapy, with NDA filing targeted for Q2 and possible commercialization early next year. Recent financing extends runway, backed by major healthcare investors.
Fiscal Year 2025
-
Clene is advancing its lead ALS therapy, CNM-Au8, toward accelerated FDA approval using biomarker data, with a New Drug Application planned for the first half of the year. If successful, commercialization could occur by late 2026 or early 2027, addressing a major unmet need.
-
Significant reductions in neurofilament and GFAP biomarkers with CNM-Au8 correlated with improved survival in ALS, especially in advanced and bulbar onset patients. The FDA is considering these biomarkers as surrogate endpoints for accelerated approval, and a Phase 3 trial with survival as the primary endpoint is planned.
-
Recent FDA engagement has advanced expanded access protocols and highlighted significant survival and biomarker benefits in ALS studies. New data under analysis may enable a new drug application by year-end, with sufficient cash to reach key milestones.
-
The conference detailed progress on CNM-Au8 for ALS and MS, highlighting survival and biomarker benefits, a strong safety profile, and ongoing FDA discussions for accelerated approval. Financial resources are sufficient to support regulatory milestones into early next year.
-
The company is advancing CNM-Au8 for ALS and MS, showing survival and biomarker benefits in clinical trials, with no serious adverse events reported. Key regulatory milestones and data readouts are expected in the coming months, with an NDA filing targeted by year-end.
-
A nanotherapeutic for ALS is advancing toward potential accelerated FDA approval, with key data on neurofilament and survival endpoints expected in the coming months. The MS program is also progressing, attracting strategic partnering interest. Cash runway extends into Q3, with several regulatory and data catalysts ahead.
-
Recent FDA meetings have set the stage for neurofilament biomarker analysis in ALS, with pivotal data collection and submission planned for Q3–Q4 and a new drug application targeted by year-end. A confirmatory phase III trial will begin late 2024, with global expansion in 2026.
-
The presentation highlighted progress in developing a gold nanocrystal therapy for ALS and MS, with strong safety data and promising secondary outcomes in survival and biomarkers. Key regulatory milestones and financial updates indicate a pivotal period ahead, with an NDA filing targeted by year-end.
-
CNM-Au8 is advancing in ALS and MS, with late-stage data showing neuron protection and remyelination. An FDA meeting is set for June, with accelerated approval filing planned for Q4 and potential approval in 2026. MS program advances toward a phase III trial.
-
Regulatory discussions have shifted to emphasize neurofilament and survival data for ALS, with a large real-world cohort and phase 3 trial underway to support accelerated approval. In MS, three-year follow-up shows cognitive and remyelination benefits, with further data and regulatory milestones expected this year.